


iSR'OBOT

MONA LISA 2.0

Robotic Precision for
Prostate Disease Management



BIOBOT

The Precision Urologists Require and Patients Deserve

Discover the future of prostate biopsies and focal therapies with our cutting-edge robotic system for transperineal prostate procedures, designed with both patients and physicians in mind

1. Robotic precision

Ensures high-accuracy needle positioning for transperineal prostate procedures

2. Advanced imaging

Features MRI-ultrasound fusion capability

3. Efficiency and consistency

Allows physicians to perform transperineal prostate procedures in a repeatable and reproducible manner



iSR:OBOT
MONA LISA 2.0

First- and Best-in-Class
Robotic Prostate Biopsy
and Treatment Solutions

Redefining the standard of care in urology
through technological innovation

A New Era in Prostate Care

Transrectal biopsy challenges

High infection risk

- + Up to 7% infection and 3% sepsis rates¹
- + 6.9% 30-day readmission rate²

Underdiagnosis

Traditional ultrasound biopsies only detect 23% of clinically significant cancers³

Limited prostate access

Transrectal biopsies cannot adequately sample the anterior or apex regions of the prostate

The New Standard of Care: Transperineal Biopsies

The standard of care is shifting to transperineal biopsies, utilizing MRI-ultrasound fusion guidance to provide:

- O1 Better visualization**
- O2 Maximal prostate coverage**
- O3 Virtually zero infection risk⁴**

But embracing this new standard without an intelligent device requires a steep learning curve that hinders adoption.⁵

The Robotic Advantage

Robotic-controlled needle positioning offers urologists the precision needed for transperineal procedures, ensuring:

O1

Higher accuracy in cancer detection⁶

O2

Repeatable and reproducible procedures

O3

A leveling of the learning curve for transperineal needle positioning

Key Features

01 **Robotic accuracy for needle positioning and depth control**
Provides precise direction and depth control for fast and accurate needle placement during biopsy and treatment, including challenging areas like the apex, anterior and peripheral zones.

02 **Flexible needle angulation with deflection adjustment**
Addresses needle deflection due to prostate tissue heterogeneity and needle tip design, ensuring accurate needle placement. Permits needle positioning at multiple angles for more custom treatment plans.

03 **Prostate stability**
Specially designed probe sheath allows the ultrasound probe to move unobstructed, minimizing prostate deformation and providing stabilization essential for accuracy.

04 **Dual-cone technology**
Mona Lisa's innovative dual-cone approach minimizes pubic arch interference during prostate biopsy, creating a virtual pivot point for multiple needle entries and ensuring maximal prostate coverage.

05 **Elastic MRI-ultrasound fusion**
Instantly merges MRI and live ultrasound models – along with prior biopsy core positions in the case of ablation – to provide physicians with 3D visualizations for precise targeting of the region of interest.

06 **Flexible planning with advanced visualizations**
Visual overlays of lesion margin and simulated ablation zones – combined with the modeling of critical structures – enable offline planning of lesion margins and needle positions. This helps to avoid ablation of critical structures reducing related side effects.

+ **→ All-in-one for biopsy and treatment**
Integrates both biopsy and treatment functionalities into a single system

Transperineal Prostate Biopsy Planning and Execution

O1 Scan and model


- + Radiologist imports MRI scan using software (UroFusion) to model prostate and mark ROI
- + Ultrasound images are automatically captured via the motorized robotic arm
- + Urologist models prostate on ultrasound images for 3D reconstruction

O2 Fuse and plan

- + Software (UroBiopsy) instantly merges MRI and ultrasound 3D models for an elastic MRI-ultrasound fusion
- + Target, Systematic and Saturation Plans auto-generate core locations based on ROI and prostate 3D model

O3 Biopsy and report

- + Robotic arm provides guidance for needle positioning based on physician-approved biopsy plans
- + Physician inserts the needle through the robotic guide
- + Automatic generation of comprehensive reports with clinical data and 3D images



Transperineal Prostate Ablation Planning and Execution

O1 Scan and model

- + Urologist prepares treatment planning offline using software (UroReview) based on pathology results
- + Motorized ultrasound probe on the robotic arm captures 2D images
- + Physician marks prostate boundaries for 3D reconstruction

O2 Fuse and plan

- + Software (UroTherapy) instantly merges MRI 3D model, ultrasound 3D model and biopsy 3D model for treatment planning
- + Visualization of insertion tools for treatment planning including visual overlays of lesion margin, critical structures and simulated ablation zones
- + Ability to import and adjust treatment plans generated offline

O3 Treat and report

- + Robotic arm provides guidance for needle positioning, automatically managing needle direction and depth based on approved treatment plans
- + Physician inserts the needles through the robotic guide
- + Conduct ablation procedure
- + Automatic generation of comprehensive reports with clinical data and 3D images

Fully Integrated System

- + iSR'obot Mona Lisa 2.0
- + UroFusion Software
- + UroBiopsy Software
- + UroReview Software
- + UroConnect Software
- + UroTherapy Software
- + Bed Rail Stabilizer / Floor Stand Stabilizer
- + iSR'obot Biopsy Kit / iSR'obot Kit

Certifications

- + EN ISO 13485:2016
- + FDA (US)
- + TGA (Australia)
- + HSA (Singapore)

Get in touch

sales@biobotsurgical.com
www.biobotsurgical.com
+65 6351 1863

Headquarters

Biobot Surgical Pte Ltd
79 Ayer Rajah Crescent #04-05
Singapore 139955

1. Kalalahti, I., Huotari, K., Erickson, A.M. et al. Infectious complications after transrectal MRI-targeted and systematic prostate biopsy. *World J Urol* 40, 2261–2265 (2022).
2. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. *J Urol* 2011; 186: 1830–1834.
3. Valerio, M., Donaldson, I., Emberton, M., Ehdai, B., Hadaschik, B. A., Marks, L. S., Mozer, P., Rastinehad, A. R., & Ahmed, H. U. (2015). Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. *European urology*, 68(1), 8–19.
4. Patel, A. & Servian, P. & Winkler, Mathias & Tiong, L.C. & Yuen, John & Ho, Hey & Chen, Kenneth & Kruck, S. & Grummet, Jeremy. (2017). Robotic MRI/US fusion transperineal biopsy using the iSR'obot Mona Lisa: Technique, safety and accuracy. *European Urology Supplements*. 16. e2092-e2093.
5. Halstuch D, Baniel J, Lifshitz D, Sela S, Ber Y, Margel D. Characterizing the learning curve of MRI-US fusion prostate biopsies. *Prostate Cancer Prostatic Dis*. 2019;22(4):546-551. DOI: 10.1038/s41391-019-0137-2.
6. Patel MI, Muter S, Vladica P, Gillatt D. Robotic-assisted magnetic resonance imaging ultrasound fusion results in higher significant cancer detection compared to cognitive prostate targeting in biopsy naive men. *Transl Androl Urol*. 2020;9(2):601-608.

DOC-00756

REV 03



biobotsurgical.com

BIOBOT